Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 5/20 | 0.50 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085451 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL2087018 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL3625740 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL2086784 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL2085382 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL2084107 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL3627707 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL2004715 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL2088202 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB | |
| SCHEMBL3628315 | 1.00 | HMGCR (0.50) | HMGCRPTPN7SELPTSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740724-B1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | ONO PHARMACEUTICAL CO (JP) | 2016-12-28 | — | — | EP | disclosed |
| EP-2308510-B1 | Agent for regeneration and/or protection of nerves | ONO PHARMACEUTICAL CO (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-9085523-B2 | Compound for treating cartilage disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20140171388-A1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2740724-A1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8501793-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130143934-A1 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-8404858-B2 | Agent for regeneration and/or protection of nerves | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2494990-A1 | Agent for regeneration and/or protection of nerves | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-05 | — | — | EP | disclosed |
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20050095281-A1 | Liposomal formulations and methods of use | OPTIME THERAPEUTICS, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004082612-A2 | LIPOSOMAL FORMULATIONS AND METHODS OF USE | OPTIME THERAPEUTICS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1156054-B1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-6495533-B1 | TUMOR NECROSIS FACTOR INHIBITORS; RHEUMATOID ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, HEPATITIS, SEPSIS, HEMORRHAGIC SHOCK, MULTIPLE SCLEROSIS, CEREBRAL INFARCTION, DIABETES, INTERSTITIAL PNEUMONIA, PAIN, HIV | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-1156054-A1 | DRUGS CONTAINING PHOSPHORIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | NONO, NAA15, USO1 | HMGCR 4004/4885PTPN7 404/4885SELP 4099/4885 |
| US-20130143934-A1 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES | PTGER3, PTGER2, PTGER1 | HMGCR 2699/4885PTPN7 2554/4885SELP 3032/4885 |
| US-20140171388-A1 | COMPOUND FOR TREATING CARTILAGE DISORDERS | COL2A1, COL1A1, ADAMTS1 | HMGCR 110/4885PTPN7 3505/4885SELP 1004/4885 |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | CXCR5, CCL11, ACKR3 | HMGCR 4249/4885PTPN7 370/4885SELP 3197/4885 |
| US-20050095281-A1 | Liposomal formulations and methods of use | LIPA, SGMS2, ABHD16A | HMGCR 477/4885PTPN7 2498/4885SELP 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.